Tags

Type your tag names separated by a space and hit enter

Acetazolamide for the treatment of idiopathic intracranial hypertension.
Expert Rev Neurother. 2015; 15(8):851-6.ER

Abstract

Idiopathic intracranial hypertension (IIH) is characterized by an increase of intracranial pressure in the absence of neurologic tumors. The sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor (CAI) acetazolamide (AAZ), a compound developed in the 1950s as a diuretic drug and presently used as an antiglaucoma, antiepileptic and diuretic agent, is effective in the treatment of IIH. AAZ is a low nanomolar inhibitor of CA isoforms involved in cerebrospinal fluid (CSF) secretion. Inhibition of brain/choroid plexus CA II, IV, VA and XII leads to a decreased CSF fluid secretion and control of the intracranial pressure. Although many sulfonamide/sulfamate CAIs are in clinical use for decades, apparently only AAZ is being currently used clinically for IIH. We speculate that more lipophilic CAIs such as methazolamide, zonisamide or topiramate should lead to a more effective control of increased intracranial pressure, thus having the opportunity to become useful in the management of IIH.

Authors+Show Affiliations

NEUROFARBA Department, Università degli Studi di Firenze, Polo Scientifico, Section of Pharmaceutical and Nutriceutical Sciences, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26154918

Citation

Supuran, Claudiu T.. "Acetazolamide for the Treatment of Idiopathic Intracranial Hypertension." Expert Review of Neurotherapeutics, vol. 15, no. 8, 2015, pp. 851-6.
Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15(8):851-6.
Supuran, C. T. (2015). Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Review of Neurotherapeutics, 15(8), 851-6. https://doi.org/10.1586/14737175.2015.1066675
Supuran CT. Acetazolamide for the Treatment of Idiopathic Intracranial Hypertension. Expert Rev Neurother. 2015;15(8):851-6. PubMed PMID: 26154918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acetazolamide for the treatment of idiopathic intracranial hypertension. A1 - Supuran,Claudiu T, Y1 - 2015/07/07/ PY - 2015/7/9/entrez PY - 2015/7/15/pubmed PY - 2016/4/15/medline KW - acetazolamide KW - carbonic anhydrase KW - choroid plexus KW - idiopathic intracranial hypertension KW - methazolamide KW - topiramate SP - 851 EP - 6 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 15 IS - 8 N2 - Idiopathic intracranial hypertension (IIH) is characterized by an increase of intracranial pressure in the absence of neurologic tumors. The sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor (CAI) acetazolamide (AAZ), a compound developed in the 1950s as a diuretic drug and presently used as an antiglaucoma, antiepileptic and diuretic agent, is effective in the treatment of IIH. AAZ is a low nanomolar inhibitor of CA isoforms involved in cerebrospinal fluid (CSF) secretion. Inhibition of brain/choroid plexus CA II, IV, VA and XII leads to a decreased CSF fluid secretion and control of the intracranial pressure. Although many sulfonamide/sulfamate CAIs are in clinical use for decades, apparently only AAZ is being currently used clinically for IIH. We speculate that more lipophilic CAIs such as methazolamide, zonisamide or topiramate should lead to a more effective control of increased intracranial pressure, thus having the opportunity to become useful in the management of IIH. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/26154918/Acetazolamide_for_the_treatment_of_idiopathic_intracranial_hypertension_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.2015.1066675 DB - PRIME DP - Unbound Medicine ER -